<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01297543</url>
  </required_header>
  <id_info>
    <org_study_id>CLT008-02</org_study_id>
    <nct_id>NCT01297543</nct_id>
  </id_info>
  <brief_title>Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia</brief_title>
  <official_title>A Phase I/II Trial of CLT-008 Myeloid Progenitor Cells in Patients Receiving Chemotherapy for Leukemia or Myelodysplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cellerant Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Health and Human Services</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Cellerant Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ex vivo expanded human myeloid progenitor cells (hMPCs; CLT-008) have the potential to
      accelerate neutrophil recovery and decrease the risk of febrile neutropenia and infection in
      patients receiving chemotherapy for acute lymphoblastic leukemia (ALL), acute myeloid
      leukemia (AML), chronic myeloid leukemia (CML), or high-risk myelodysplasia (MDS). In this
      study, the safety, tolerability and activity of CLT-008 administered after &quot;standard of care&quot;
      cytarabine-based consolidation or induction/re-induction chemotherapy will be determined by
      monitoring for adverse reactions, infusion reactions, graft-versus host disease (GVHD),
      neutrophil and platelet recovery, hMPC persistence, infections and complications.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of serious adverse reactions</measure>
    <time_frame>Consolidation patients-43 days post dose and Induction/re-induction patients-40 days post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of neutropenia</measure>
    <time_frame>Consolidation patients-43 days post dose and Induction/re-induction patients-40 days post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of thrombocytopenia</measure>
    <time_frame>Consolidation patients-43 days post dose and Induction/re-induction patients-40 days post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of presence of CLT-008 derived cells in blood</measure>
    <time_frame>Consolidation patients-43 days post dose and Induction/re-induction patients-40 days post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of presence of CLT-008 derived cells in bone marrow</measure>
    <time_frame>Consolidation patients-43 days post dose and Induction/re-induction patients-40 days post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of mucositis</measure>
    <time_frame>Consolidation patients-43 days post dose and Induction/re-induction patients-40 days post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infections</measure>
    <time_frame>Consolidation patients-43 days post dose and Induction/re-induction patients-40 days post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of fever</measure>
    <time_frame>Consolidation patients-43 days post dose and Induction/re-induction patients-40 days post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of antibiotic use</measure>
    <time_frame>Consolidation patients-43 days post dose and Induction/re-induction patients-40 days post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hospitalization</measure>
    <time_frame>Consolidation patients-43 days post dose and Induction/re-induction patients-40 days post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>Consolidation patients-43 days post dose and Induction/re-induction patients-40 days post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Chronic Myeloid Leukemia</condition>
  <condition>Myelodysplasia</condition>
  <arm_group>
    <arm_group_label>Consolidation Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose CLT-008 (human myeloid progenitor cells)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Consolidation Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intermediate dose CLT-008 (human myeloid progenitor cells)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Consolidation Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intermediate dose CLT-008 (human myeloid progenitor cells), no G-CSF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Consolidation Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose CLT-008 (human myeloid progenitor cells)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Induction Group A1 (cytarabine 7+3)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>G-CSF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Induction Group A2 (cytarabine 7+3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intermediate dose CLT-008 (human myeloid progenitor cells)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Induction Group A3 (cytarabine 7+3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose CLT-008 (human myeloid progenitor cells)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Induction Group B1 (cytarabine HIDAC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>G-CSF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Induction Group B2 (cytarabine HIDAC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intermediate dose CLT-008 (human myeloid progenitor cells)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Induction Group B3 (cytarabine HIDAC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose CLT-008 (human myeloid progenitor cells)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>human myeloid progenitor cells</intervention_name>
    <description>Single intravenous injection/infusion</description>
    <arm_group_label>Consolidation Group A</arm_group_label>
    <arm_group_label>Consolidation Group B</arm_group_label>
    <arm_group_label>Consolidation Group C</arm_group_label>
    <arm_group_label>Consolidation Group D</arm_group_label>
    <arm_group_label>Induction Group A2 (cytarabine 7+3)</arm_group_label>
    <arm_group_label>Induction Group A3 (cytarabine 7+3)</arm_group_label>
    <arm_group_label>Induction Group B2 (cytarabine HIDAC)</arm_group_label>
    <arm_group_label>Induction Group B3 (cytarabine HIDAC)</arm_group_label>
    <other_name>CLT-008</other_name>
    <other_name>hMPC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>Background therapy</description>
    <arm_group_label>Consolidation Group A</arm_group_label>
    <arm_group_label>Consolidation Group B</arm_group_label>
    <arm_group_label>Consolidation Group D</arm_group_label>
    <arm_group_label>Induction Group A1 (cytarabine 7+3)</arm_group_label>
    <arm_group_label>Induction Group A2 (cytarabine 7+3)</arm_group_label>
    <arm_group_label>Induction Group A3 (cytarabine 7+3)</arm_group_label>
    <arm_group_label>Induction Group B1 (cytarabine HIDAC)</arm_group_label>
    <arm_group_label>Induction Group B2 (cytarabine HIDAC)</arm_group_label>
    <arm_group_label>Induction Group B3 (cytarabine HIDAC)</arm_group_label>
    <other_name>filgrastim</other_name>
    <other_name>granulocyte colony stimulating factor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Hematological malignancy, including:

               -  AML, ALL or MDS

          -  Planned treatment with cytarabine-based chemotherapy regimen

          -  Adequate hepatic, renal, hematologic, cardiac and respiratory function

        Key Exclusion Criteria:

          -  Prior allograft or history of active GVHD within 3 years

          -  Pregnant or nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Moores UCSD Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Hospital and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center, Cardinal Bernardin Cancer Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Blood and Marrow Transplantation, LLC</name>
      <address>
        <city>Beech Grove</city>
        <state>Indiana</state>
        <zip>46107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Memorial Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Western Pennsylvania Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cellerant.com</url>
    <description>Cellerant Therapeutics, Inc.</description>
  </link>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2011</study_first_submitted>
  <study_first_submitted_qc>February 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2011</study_first_posted>
  <disposition_first_submitted>May 10, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>May 10, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 3, 2016</disposition_first_posted>
  <last_update_submitted>June 29, 2016</last_update_submitted>
  <last_update_submitted_qc>June 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Induction chemotherapy</keyword>
  <keyword>Re-induction chemotherapy</keyword>
  <keyword>Consolidation chemotherapy</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Myelodysplasia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

